Shitara, Kohei
Ueha, Satoshi
Shichino, Shigeyuki
Aoki, Hiroyasu
Ogiwara, Haru
Nakatsura, Tetsuya
Suzuki, Toshihiro
Shimomura, Manami
Yoshikawa, Toshiaki
Shoda, Kayoko
Kitano, Shigehisa
Yamashita, Makiko
Nakayama, Takayuki
Sato, Akihiro
Kuroda, Sakiko
Wakabayashi, Masashi
Nomura, Shogo
Yokochi, Shoji
Ito, Satoru
Matsushima, Kouji
Doi, Toshihiko
Funding for this research was provided by:
Japan Agency for Medical Research and Development (16768526)
Article History
Received: 2 December 2018
Accepted: 11 July 2019
First Online: 24 July 2019
Ethics approval and consent to participate
: This study was approved by the Institutional Review Board of the National Cancer Center (K0588) and was conducted in accordance with international ethics guidelines, including the Declaration of Helsinki. We obtained written informed consent from all participants.
: No individual data were used in this study.
: KS reports consulting or advisory role for Astellas, Lilly, Bristol-Myers Squibb, Takeda, Pfizer, and Ono; personal fees from Novartis, AbbVie, and Yakult; and research funding from Lilly, Ono, Sumoitomo Dainippon, Daiichi Sankyo, Taiho, Chugai, and MSD.SU reports Stock or Other Ownership for IDAC Theranostics, Inc.TN reports research funding from IDAC Theranostics, Inc.SK reports personal fees from Astra Zeneca, Chugai, Pfizer, Sanofi, Nippon Kayaku, Boehringer Ingelheim, Meiji Seika Pharma, Taiho, Novartis, Daiichi-Sankyo, MSD, Kyowa Hakko Kirin, Celgene, Sumitomo Dainippon Pharma, Bristol-Myers Squibb, Ono and Eisai; grants from Eisai, REGENERON, Astellas, Gilead Sciences, AMED (Japan.Agency for Medical Research and Development) and JSPS (Japan Society for the.Promotion of Science).AS reports Speakers Bureau for Astra Zeneca.SN report employment for Asahi-Kasei Pharma.; Honoria from Taiho Pharmaceutical.SY reports employment for IDAC Theranostics, Inc.; Stock or Other Ownership for.IDAC Theranostics, Inc.SI reports employment and leader ship for IDAC Theranostics, Inc.; Stock or Other Ownership for IDAC Theranostics, Inc.KM reports consulting or advisory role for Kyowa-Hakko Kirin; research funding from Kyowa-Hakko Kirin, and Ono; Stock or Other Ownership for IDAC Theranostics, Inc.TD reports consultancy for Lilly, Chugai, Kyowa Hakko Kirin, MSD, Daiichi Sankyo, Amgen, Sumitomo Dainippon, and Taiho; research funding from Taiho, Novartis, Merck.Serono, Astellas, MSD, Janssen, Boehringer Ingelheim, Takeda, Pfizer, Lilly,Sumitomo Dainippon, Chugai Pharma, Kyowa Hakko Kirin, Daiichi Sankyo, Celgene,Bristol-Myers Squibb, Abbvie, and Quintiles.SS, HA, HO, TS, MS, TY, KS, MY, TN, SK, and MW have no conflict of interests to report.